Savara to present IMPALA trial analysis and long-term molgramostim data at CHEST 2026

The company said it will present a new analysis from the IMPALA clinical trial and deliver an encore presentation of long-term data on molgramostim for autoimmune pulmonary alveolar proteinosis.